Is risperidone more effective than other pharmacologic treatments for reducing irritability, aggression, and self‑injurious behavior in individuals with autism spectrum disorder?

Risperidone vs Other Medications for Autism Spectrum Disorder

Risperidone is FDA-approved and has the strongest evidence for treating irritability, aggression, and self-injurious behavior in autism, but it does not appear to be significantly more effective than aripiprazole, and both show only small effect sizes compared to non-pharmacological interventions.

Evidence Hierarchy and Key Findings

FDA-Approved Medications

Only two antipsychotics have FDA approval for autism-related irritability 1:

• Risperidone: Approved for ages 5-17 years, demonstrated 69% positive response vs 12% placebo, with significant improvements in irritability, hyperactivity, and stereotypy 2
• Aripiprazole: Approved for ages 6-17 years, showed 56% positive response vs 35% placebo, with improvements in irritability, hyperactivity, and stereotypy 2

Direct Comparison Data

The only head-to-head comparison found risperidone superior to haloperidol on ABC total score only, with no significant differences on individual subscales 2. Notably, haloperidol caused extrapyramidal symptoms in >25% of patients, while risperidone's side effect profile was more tolerable 2.

Broader Context from Meta-Analysis

A 2023 Lancet Psychiatry systematic review found no significant differences between pharmacological and non-pharmacological interventions for behaviors that challenge in intellectual disability populations (which includes autism) 3. All interventions showed only small effect sizes across multiple topographies of behavior.

Clinical Decision Algorithm

Step 1: Start with non-pharmacological interventions

• Functional behavior assessment-informed interventions
• Parent training (combining with medication is moderately more efficacious than medication alone) 2
• Vigorous aerobic exercise 4

Step 2: Consider pharmacotherapy when:

• Risk of harm from behaviors is severe
• Non-pharmacological interventions are ineffective or unavailable
• Specific target symptoms exist (aggression, self-injury, severe tantrums)

Step 3: If medication indicated, choose risperidone or aripiprazole

• Risperidone: 0.5-3.5 mg/day (or 0.02-0.06 mg/kg/day), starting at 0.25-0.5 mg/day based on weight 2, 1
• Aripiprazole: 5-15 mg/day, flexibly dosed 2

Both have comparable efficacy; choice depends on side effect profile tolerance.

Critical Side Effect Considerations

Risperidone-Specific Risks

• Weight gain: Most significant concern, with mean gain of 2 kg in 3-8 weeks (vs 0.6 kg placebo), 5.5 kg at 24 weeks, and 8 kg at 48 weeks 1
• Metabolic effects: Increased appetite, somnolence (most common), drooling, fatigue 2, 1
• Therapeutic window: 3.5-7 ng/mL (some data suggest 5.0-8.0 ng/mL) for sum of risperidone and 9-OH-risperidone 5
• CYP2D6 variability: Significant pharmacokinetic differences based on metabolizer status 6

Aripiprazole-Specific Risks

• Somnolence, weight gain, drooling, tremor, fatigue, vomiting 2
• Generally similar metabolic profile to risperidone

Comparative Advantage

Risperidone has more extensive pediatric data and longer clinical experience in autism populations, but this does not translate to superior efficacy over aripiprazole.

Important Caveats

Risperidone is not "better" than other medications in a clinically meaningful way - the evidence shows:

1. Small effect sizes overall for all pharmacological interventions 3
2. No demonstrated superiority over aripiprazole (both FDA-approved)
3. Only one comparison showing marginal benefit over haloperidol on total scores 2
4. Significant metabolic risks that accumulate over time 1

The 2014 AACAP guidelines emphasize that pharmacotherapy should target specific symptoms or comorbid conditions, not core autism features 2. The goal is to facilitate engagement with educational and behavioral interventions, not to replace them.

Monitoring Requirements:

• Weight and metabolic parameters at baseline and regularly during treatment 1
• Use objective rating scales (ABC, CGI-C) to document response 2
• Consider therapeutic drug monitoring, especially with poor response or side effects 5

The evidence supports risperidone as one of two first-line pharmacological options when medication is necessary, but it should not be viewed as superior to aripiprazole, and both should be used only when behavioral interventions are insufficient given the modest benefits and significant metabolic risks 3, 2, 1, 4.